PAN India Service 

WHO Certified

Blood-based Tumour Mutational Burden Assay Predicts Clinical Benefit in NSCLC Patients Treated with Atezolizumab

Blood-based Tumour Mutational Burden Assay Predicts Clinical Benefit in NSCLC Patients Treated with Atezolizumab Results based on retrospective analysis of two large randomised trials

I. Blood-based Tumour Mutational Burden Assay Predicts Clinical Benefit in NSCLC Patients Treated with Atezolizumab
Results based on retrospective analysis of two large randomised trials. Date: 17 Aug 2018

II. Eisai, Merck take on Bayer's Nexavar with new liver cancer nod for Lenvima. Aug 17, 2018 10:15 am

Leave a Comment

(0 Comments)

Your email address will not be published. Required fields are marked *